Top chart analyst Jeff deGraaf explains why technical analysis should be a key part of your investing process.» Read More
Oct 27- U.S. health regulators on Tuesday approved Amgen Inc's novel cancer immunotherapy for injection into melanoma lesions and lymph nodes for patients with the deadliest form of skin cancer that returns after initial surgery. Amgen said it expects the average cost of Imlygic therapy to be about $65,000, and that it will be available to U.S. patients within a...
Oct 27- Amgen Inc said on Tuesday that the U.S. Food and Drug Administration approved its cancer immunotherapy, Imlygic, for use in patients with the most deadly type of skin cancer.
Oct 27- Amgen Inc and Cytokinetics Inc said on Tuesday their experimental drug for chronic heart failure showed significant improvement in cardiac function in the second part of a mid-stage study. Omecamtiv mecarbil, which Amgen licensed from Cytokinetics, takes a novel approach to tackling heart failure by activating cardiac myosin, a protein in heart...
It's the busiest week for earnings with more than 150 S&P companies set to report. The options market is implying big moves for some widely held names.
As the earnings kicks into high gear, a group of stocks could be ready to pop, if history is any guide.
Expectations are low that the Fed will provide any new policy insight next week, and focus should stay on economic reports and a flood of earnings.
LONDON, Oct 23- A first-in-class drug from Amgen based on a tumour-killing virus was given a green light by European regulators on Friday, paving the way for its approval within a couple of months. The European Medicines Agency said its experts had recommended approval of Imlygic, also known as talimogene laherparepvec or "T-Vec", for treating melanoma, making it...
Oct 16- The most influential source for U.S. oncology treatment guidelines on Friday unveiled ratings aimed at helping doctors and patients assess the costs versus benefits of current therapies for two types of blood cancer. Craig Hofmeister, a hematologist with the Ohio State University Comprehensive Cancer Center and a member of the NCCN myeloma...
In examples released on Friday, NCCN rated primary treatments for CML: Bristol-Myers Squibb's Sprycel, and Novartis AG's Gleevec and Tasigna. For newly diagnosed myeloma patients eligible for a stem cell transplant, NCCN lists six "preferred" regimens, four of which contain Takeda Pharmaceutical Co's Velcade and various chemotherapies, one that includes...
The same drug development news that's hurting Eli Lilly shares might be good for Amgen and Sanofi-Regeneron.
*EMC shares rise after Dell offer. Oct 12- Gains in utility stocks offset a retreat in energy shares on Monday, leaving U.S. stocks near flat as investors remained nervous about third-quarter corporate results. Trading in equities was also affected by the closing of the bond market, banks and the government, including the Securities and Exchange Commission, for...
*EMC shares rise after Dell offer; VMware falls. Trading in equities was also affected by the closure of the bond market, banks and the government, including Securities and Exchange Commission, for the Columbus Day holiday. JPMorgan reports on Tuesday, with Goldman Sachs, Bank of America, Wells Fargo and Citigroup posting results through the week.
*EMC shares rise after Dell offer. Health stocks were down after Eli Lilly said it was scrapping an experimental heart drug and taking a related charge in the fourth quarter. EMC's shares were up 2.6 percent at $28.60 after Dell said it would buy the data storage company in a $67 billion deal.
Stock markets are fixated on Fed policy, but two experts believe investors should forget the U.S. central bank for now.
*Regeneron, Amgen lead health care sector. Brands hit by China woes. Investors' focus is turning to earnings, and Yum!
*Regeneron, Amgen lead health care sector. *Yum Brands hit by China woes, drags McDonald's. slumped 19 percent, while McDonald's, which also has a large exposure to China, fell 0.5 percent to $101.12.
Express Scripts, the largest pharmacy benefits manager in the U.S., says it's got a plan to fight drug price increases: Refuse to pay.
Some of the names on the move ahead of the open.
U.S. stock futures powered higher this morning, after the Dow eked out its third straight gain in Tuesday's mixed session on Wall Street.
The nation's biggest pharmacy benefits manager has decided to cover two new drugs that lower artery-clogging cholesterol.